Netflix Q3 2026 Earnings Set for Oct. 20

Netflix Q3 2026 earnings on Oct. 20 will concentrate traders' positioning on management's post-close video interview and guidance for revenue and margins.

October 02, 2026·2 min read
View all news articles
Flat-vector film reel with dimming spotlight to symbolize scrutiny ahead of Netflix Q3 2026 earnings and margin focus.

KEY TAKEAWAYS

  • Netflix scheduled Q3 2026 results for Oct. 20 with a post-close video interview.
  • Second-quarter revenue was $12.6 billion and operating margin about 33.4%.
  • Prior guidance targeted roughly $12.9 billion revenue and a 33.2% operating margin.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Netflix Inc. (NFLX) will release its third-quarter 2026 earnings after the market close on Oct. 20, 2026, the company said in an investor-relations release on Sept. 14. Management will follow with a video interview featuring co-CEOs Greg Peters and Ted Sarandos and CFO Spence Neumann, focusing attention on revenue and margin outlooks.

Netflix Sets Oct. 20 Earnings Date

Netflix scheduled publication of its third-quarter 2026 results for Oct. 20 after the market close. The company said management would hold a video interview with co-CEOs Peters and Sarandos and CFO Neumann to discuss the results and outlook.

Results, Guidance, and Outlook

Netflix reported second-quarter 2026 revenue of $12.56 billion, a 13.4% increase year over year, with diluted earnings per share of $0.80 and an operating margin of 33.4%. Prior guidance called for roughly $12.86 billion in third-quarter revenue and a 33.2% operating margin, implying about 11.7% year-over-year revenue growth.

Full-year 2026 operating-margin guidance stood at 31.5%, with management expecting operating income to rise more than 20% year over year. Analysts’ consensus estimates ahead of the report placed third-quarter diluted EPS near $0.82 and revenue between $12.87 billion and $12.88 billion.

Advertising revenue is expected to roughly double year over year to about $3 billion, shifting growth toward ad-supported streams and raising questions about engagement versus monetization. Nielsen data cited in recent reports showed YouTube accounted for 14.2% of U.S. television time in July, compared with 7.8% for Netflix, providing context for competitive pressures.

Analyst actions in September included Wells Fargo downgrading Netflix to underweight with a $57 target on Sept. 18 and HSBC lowering its rating to hold with a $76 target on Sept. 22.

The upcoming third-quarter release and management commentary will test the company’s guidance and assumptions on advertising and margins, likely influencing analyst estimates for the next quarter.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Nike Earnings Reveal Weak Sales and Pace Restructuring

Nike Earnings Reveal Weak Sales and Pace Restructuring

Nike earnings showed weaker sales and unveiled Pace, a restructuring that targets $2.5B in savings and will reduce roles, pressuring the fiscal outlook.

Broadcom Anthropic Financing Up To $42 Billion

Broadcom Anthropic Financing Up To $42 Billion

Broadcom Anthropic financing of up to $42 billion appears in Anthropic's IPO prospectus, raising concentration and financing risk for IPO investors.

Synopsys Investor Day Raises Growth Targets

Synopsys Investor Day Raises Growth Targets

Synopsys Investor Day raised long-term revenue and margin targets on AI demand and unveiled GPT-Synopsys with OpenAI, likely supporting shares.

McCormick Q3 Results Beat Sales Estimates

McCormick Q3 Results Beat Sales Estimates

McCormick Q3 results beat sales and margins and reaffirmed guidance while raising cost inflation, pushing traders to weigh margins versus higher costs.

Liquidia Patent Ruling Threatens YUTREPIA U.S. Sales

Liquidia Patent Ruling Threatens YUTREPIA U.S. Sales

Liquidia patent ruling found YUTREPIA infringes UTHR's patent, raising the prospect of an FDA-directed withdrawal and prompting investor scrutiny.

Sanofi Regeneron Alliance Expands Pipeline

Sanofi Regeneron Alliance Expands Pipeline

Sanofi Regeneron alliance adds four long-acting antibodies with $1 billion upfront and equal cost and profit sharing, a framework investors will weigh.